Results 111 to 120 of about 48,370 (295)

Transgenic chickens expressing human urokinase-type plasminogen activator

Poultry Science, 2013
Urokinase-type plasminogen activator is a serine protease that is clinically used in humans for the treatment of thrombolytic disorders and vascular diseases such as acute ischemic stroke and acute peripheral arterial occlusion. This study explored the feasibility of using chickens as a bioreactor for producing human urokinase-type plasminogen ...
Sung Ho, Lee, Mukesh Kumar, Gupta, Young Tae, Ho, Teoan, Kim, Hoon Taek, Lee   +4 more
openaire   +2 more sources

Single‐Cell and Multiomic Analysis Reveals Neutrophil Heterogeneity and Prognostic Value in Cervical Lesions

Cancer Science, EarlyView.
This study is the first to identify a novel neutrophil subpopulation, N4, that is closely associated with the progression of cervical cancer. Characterized by high PLAU expression and specific interactions with tumor cells, N4 neutrophils were shown to promote tumor growth and immune modulation.
Ze Wang, Liang Zhuang, Shiyi Liu, Canhui Cao, Shimin Chen, Nan Yu, Xiaoyuan Huang, Tao Zhang   +7 more
wiley   +1 more source

Functional Stability of Plasminogen Activator Inhibitor-1

The Scientific World Journal, 2014
Plasminogen activator inhibitor-1 (PAI-1) is the main inhibitor of plasminogen activators, such as tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA), and a major regulator of the fibrinolytic system.
Songul Yasar Yildiz, Pinar Kuru, Ebru Toksoy Oner, Mehmet Agirbasli   +3 more
doaj   +1 more source

Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels [PDF]

, 2013
The soluble cleaved urokinase plasminogen activator receptor (scuPAR) is a circulating protein detected in multiple diseases, including various cancers, cardiovascular disease, and kidney disease, where elevated levels of scuPAR have been associated with
Andrew J. Wardlaw, Behrendt N., Blasi F., Ceri E. Stewart, Dirkje S. Postma, Gerard H. Koppelman, Ian Sayers, Janine Altmuller, Judith M. Vonk, Maartje A. Nieuwenhuis, Martin J. Connolly, Mateusz Siedlinski, Mazzieri R., Michael A. Portelli, Miriam F. Moffatt, Peter Nurnberg, Plesner T., Ploug M., Schmaier A. H., Sidenius N., Stewart C. E., Stewart C. E., Stuart G. Parker, Tan X., Team R. C.   +24 more
core   +5 more sources

Extracellular matrix and proteolysis: mechanisms driving irreversible changes and shaping cell behavior

The FEBS Journal, EarlyView.
Irreversible ECM proteolysis by remodeling enzymes shapes development, homeostasis, and disease. ECM‐degrading proteases display cell specificity and are governed by shared mechanisms, exhibiting functional redundancy in generating matrikines, growth factors, and cytokines.
Inna Solomonov, Orit Kollet, Irit Sagi
wiley   +1 more source

Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications

Frontiers in Oncology, 2018
The plasminogen activator (PA) system is an extracellular proteolytic enzyme system associated with various physiological and pathophysiological processes.
Niaz Mahmood, Catalin Mihalcioiu, Shafaat A. Rabbani, Shafaat A. Rabbani   +3 more
doaj   +1 more source

Targeting the microbiota‐miRNA‐protease axis: A new therapeutic avenue in melanoma

The FEBS Journal, EarlyView.
Modulation of extracellular matrix (ECM) turnover is central to melanoma progression and metastasis, driven largely by ECM proteases. This review highlights the epigenetic regulation of ECM proteases by microRNAs and their roles in melanoma growth, invasion, and immune modulation.
Elias N. Katsoulieris, Paraskevi Ioannou, Nikolaos A. Afratis   +2 more
wiley   +1 more source

Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator

Scientific Reports, 2017
Although trypsin-like serine proteases have flexible surface-exposed loops and are known to adopt higher and lower activity conformations, structural determinants for the different conformations have remained largely obscure.
Tobias Kromann-Hansen, Eva Louise Lange, Hans Peter Sørensen, Gholamreza Hassanzadeh-Ghassabeh, Mingdong Huang, Jan K. Jensen, Serge Muyldermans, Paul J. Declerck, Elizabeth A. Komives, Peter A. Andreasen   +9 more
doaj   +1 more source

Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission. [PDF]

, 2015
Background: Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker increasingly used for the assessment of systemic inflammation.
Aletaha, Aletaha, Aletaha, Aletaha, Behrendt, Behrendt, Brünner, Brünner, ICSH, ICSH, Ostergaard, Ostergaard, Ostrowski, Ostrowski, Riisbro, Riisbro, Rønne, Rønne, Sier, Sier, Sier, Sier, Stephens, Stephens, Thunø, Thunø, Toldi, Toldi, Wells, Wells   +29 more
core   +1 more source

Activation of the Urokinase Plasminogen Activator/Urokinase Plasminogen Activator Receptor System in Periodontitis: A Case–Control Study

International Journal of Dental Hygiene, EarlyView.
ABSTRACT Introduction The plasminogen activating (PA) system has a multitude of functions such as wound healing, proteolytic activity, collagen degradation and cell growth, and the role of the urokinase plasminogen activator/urokinase plasminogen activator receptor (uPA/uPAR) system has been studied in many disease states.
Ahmed Khudhur, Christopher Dowson, Susan M. Bissett, Rachel van de Merwe, John J. Taylor, Philip M. Preshaw, Katrin M. Jaedicke   +6 more
wiley   +1 more source